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The “Potential therapeutic strategy to treat substance-abuse-related disorders” session was
chaired by Dr. Sulie L. Chang, director of NeuroImmune Phamacology at Seton Hall Uni-
versity. The four presenters were: Dr Wenzhe Ho (Miniway to stop HIV/HCV), Dr Ru-Band
Lu (Low dose of memantine in the treatment of opioid dependence in human), Dr Ping
Zhang (Treatment of alcohol-related disorders: Learning from stem/progenitor cells), and
Dr Yun-Hsiang Chen (Treatment of methamphetamine abuse: An antibody-based immu-
notherapy approach).
Copyright ª 2013, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. Open access under CC BY-NC-ND license.1. Introduction Substances of abuse can alter neuronal and immune path-Speakers at the symposium delineated the multidirectional
interaction between the central nervous system (CNS), the
immune system, and substances of abuse in the presence of
human immunodeficiency virus (HIV) infection, both in vivo
and in vitro. They also discussed the translation of findings
from animal behavioral studies into the clinical setting in
relation to the potential for developing new therapeutic stra-
tegies for HIV-1-infected patients who use addictive
substances.2. Presentations
Since the early 1990s, the link between the CNS and the im-
mune system has been demonstrated through the converging
actions of substances of abuse such as alcohol and opiates,
cytokines such as interleukin-1 (IL-1), and the brain [1].mune Pharmacology, Se
ministration, Taiwan. Publways via modulation of the hypothalamicepituitaryeadrenal
(HPA) axis [2], and high concentrations of ethanol (> 32%) can
activate the vasopression neurons responsible for osmoregu-
lation in the hypothalamic supraoptic nucleus [3]. Chronic
exposure to opiates such as morphine potentiates immune
responses to an exogenous challenge with IL-1 by desensi-
tizing the HPA response [2] and accelerates the progression of
sepsis caused by the bacterial endotoxin lipopolysaccharide
(LPS) to septic shock [4]. In the HIV-1Tg rat, a non-infectious
rodent model for patients on highly active antiretroviral
therapy (HAART), exposure to LPS increases cytokine levels in
the brain. Furthermore, HIV-1Tg rats are more responsive to
addictive drugs, including morphine, methamphetamine, and
alcohol, compared to control rats [1]. Investigation of the
mechanisms behind the heightened response to morphine
revealed that LPS increases expression of the mu opioid re-
ceptor (MOR), the receptor for morphine, to a greater extent in
HIV-1Tg rats than in control rats, indicating that there may beton Hall University, 400 South Orange Avenue, South Orange, NJ
ished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
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fections that renders HIV-1-infected individuals more sus-
ceptible to morphine dependence [1,5].
Various mechanisms have been proposed regarding the
interaction of substance abuse and the immune system.
While investigating the negative impact of viral infection and
opioids on the innate defense mechanism of host cells, Dr
Wenzhe Ho and his team found that activation of Toll-like
receptor 3 (TLR3) in macrophages results in induction of
multiple anti-HIV cellular factors (CC-chemokines, tetherin,
interferon-stimulated genes, andmiRNAs) and suppression of
HIV infection/replication. Furthermore, they found that TLR3
activation in hepatocytes by poly I:C could inhibit hepatitis C
virus (HCV) replication. These in vitro observations clearly
indicate the importance of TLR3 signaling in protecting host
cells from HIV or HCV infection. Thus, future investigations
are necessary to determine whether in vivo activation of TLR3
has a protective effect on HIV and/or HCV infection in the
context of opioid use.
Interestingly, it has been reported that the Alzheimer’s
disease medication memantine decreases LPS-induced
microglial activation at low doses, possibly by reducing the
production of inflammatory cytokines, and decreases
morphine-induced conditioned place preference (CPP) partly
via its anti-inflammatory effects. In terms of clinical applica-
tions, anti-inflammatory benefits of low-dose memantine, as
discussed by Dr Ru-Band Lu in his presentation, have been
demonstrated in patients receiving methadone maintenance
therapy (MMT). Patients receiving methadone treatment tend
to become tolerant and dependent on the substance. To test
the efficacy of low-dose memantine as an adjuvant thera-
peutic intervention for opioid-dependent patients during
long-termMMT, Dr Lu and his team treated patients with low-
dose memantine prior to MMT. Patients pretreated with
memantine showed attenuated methadone tolerance, lower
plasma IL-8, and increased transforming growth factor (TGF)-
b1 and BDNF expression. Dr Lu proposed that the anti-
addictive mechanism of low-dose memantine may be attrib-
uted, at least in part, to its anti-inflammatory and neuro-
protective effects, as well as its ability to upregulate BDNF
production.
Alcohol impairs a critical step of the granulopoietic
response, which is associated with emergency expansion of
LKS cell populations and thus with reprogramming of primi-
tive precursors to enhance their commitment to granulocyte
lineage development. However, the mechanisms underlying
this association are not yet understood. Dr Ping Zhang and his
group investigated the mechanisms by which alcohol dam-
ages immune defense function to identify therapeutic targets
for effective treatment of alcoholic patients with severe bac-
terial infection. They found that alcohol-induced disruption of
leukemia stem/progenitor cell (LSPC) function may serve as a
target for future development of effective therapy to treat
alcoholic liver disease. This is based on the findings that
incorporation of bromodeoxyuridine (BrdU) into proliferating
LSPCs is dose-dependently inhibited by ethanol. Cyclin D1
mRNA expression by LSPCs is suppressed by exposure to50 mM or 100 mM ethanol, and phase imaging has revealed
that alcohol exposure induces amorphological change in LSPC
differentiation towards a myofibroblast-like phenotype. Dr
Zhang reported that expression of E-cadherin by LSPCs
cultured in differentiation medium was downregulated by
ethanol, which was accompanied by significant upregulation
of Snail repressor gene expression. Finally, alcohol inhibited
LSPC self-renewal and promoted epithelial-to-mesenchymal
transition during differentiation. Dr Zhang’s findings impli-
cate several possible mechanisms by which alcohol may
impair cell immune functions. This research has important
implications for immunocompromised patients such as those
with HIV or leukemia.
Taken together, these studies suggest that targeting of
systemic inflammation using anti-inflammatory agents may
be beneficial for protection against HIV infection and behav-
ioral disorders related to substance abuse. In addition to
pharmacological therapeutic techniques, antibody-based im-
munotherapies, such as those discussed by Dr Yun-Hsiang
Chen, have provided information regarding the mechanisms
by which dependence on substances of abuse may be medi-
ated. Dr Chen and colleagues generated a recombinant adeno-
associated virus vector encoding heavy and light chains of a
characterized anti-methamphetamine monoclonal antibody
and found expression of full-length and functional mono-
clonal antibodies both in vitro and in vivo. This team also found
evidence of virus-induced attenuation of locomotor activity
induced by methamphetamine (1 mg/kg, intraperitoneal in-
jection). This novel therapeutic strategy could assist in better
treatment of dependence on methamphetamine and other
substances of abuse.
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